- Home
- SOWG vs CANF Comparison
SOWG vs CANF Comparison
Compare SOWG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- CANF
- Stock Information
- Founded
- SOWG 2010
- CANF 1994
- Country
- SOWG United States
- CANF Israel
- Employees
- SOWG N/A
- CANF N/A
- Industry
- SOWG Packaged Foods
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- CANF Health Care
- Exchange
- SOWG Nasdaq
- CANF Nasdaq
- Market Cap
- SOWG 8.8M
- CANF 9.6M
- IPO Year
- SOWG N/A
- CANF N/A
- Fundamental
- Price
- SOWG $0.82
- CANF $0.65
- Analyst Decision
- SOWG
- CANF Strong Buy
- Analyst Count
- SOWG 0
- CANF 2
- Target Price
- SOWG N/A
- CANF $14.50
- AVG Volume (30 Days)
- SOWG 115.8K
- CANF 163.5K
- Earning Date
- SOWG 11-12-2025
- CANF 08-26-2025
- Dividend Yield
- SOWG N/A
- CANF N/A
- EPS Growth
- SOWG N/A
- CANF N/A
- EPS
- SOWG N/A
- CANF N/A
- Revenue
- SOWG $9,271,376.00
- CANF $560,000.00
- Revenue This Year
- SOWG $6.81
- CANF $461.72
- Revenue Next Year
- SOWG N/A
- CANF N/A
- P/E Ratio
- SOWG N/A
- CANF N/A
- Revenue Growth
- SOWG N/A
- CANF N/A
- 52 Week Low
- SOWG $0.51
- CANF $0.63
- 52 Week High
- SOWG $13.55
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- SOWG 54.79
- CANF 35.49
- Support Level
- SOWG $0.70
- CANF $0.64
- Resistance Level
- SOWG $0.88
- CANF $0.68
- Average True Range (ATR)
- SOWG 0.07
- CANF 0.02
- MACD
- SOWG 0.02
- CANF 0.01
- Stochastic Oscillator
- SOWG 73.50
- CANF 40.00
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).